Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Mar 06, 2018 5:51pm

177 Views

Post# 27671770

RE:RE:RE:Quick projection

PoorOpinion wrote:

CandideV007 wrote:

jfm1330 wrote: Let's say in two years we reach 4,000 patients in the US and by then the net drug price should be at 90,000 and let'assume a conservative currency exchange rate of 1.20. It means

4,000 x 90,000 x 1.20 x 0.48 = 207 M$ in profits with 76 M shares it means EPS of 2.72 $. With a conservative multiple of 20 it means a SP at 55$. All that without taking into consideration Europe and Canada and 4,000 patients it think is a relatively conservative number. So to sell at 15$ is likely leaving 40$ on the table and probably more. Obviously we will have to pay the milestone payments along the way, but I think it roughly shows the potential.

Those are not profits but revenues. Considering that half is going to Taimed, your calculation should be divided by half.

Then you need to substract the production cost + salaries + etc.

That leads us to an expected value around 20$.

Considering the money Taimed will lose to Theratech, and considering its current market cap, I'm convinced that this company will receive a buying offer. Let's hope it will be much higher than 1.0-1.2 G$.

I think the 0.48 accounts for the thera 'half' of the revenue. Generally its assumed that EGRIFTA sales are covering all costs. Taimed pay production costs of the drug that is covered by their 52% of sales. It worth checking the contract details on Sedar it outlines a lot of the details on how thera pays taimed, manufacturing, shipping etc (around mar-apr 2016)